Abstract
Population heterogeneity in bacterial phenotypes, such as antibiotic resistance, is increasingly recognized as a medical concern. Heteroresistance (HR) occurs when a predominantly susceptible bacterial population harbors a rare resistant subpopulation. During antibiotic exposure, these resistant bacteria can be selected and lead to treatment failure. Standard antibiotic susceptibility testing (AST) methods often fail to reliably detect these subpopulations due to their low frequency, highlighting the need for new diagnostic approaches. Here, we present a droplet microfluidics method where bacteria are encapsulated in droplets containing growth medium and antibiotics. The growth of rare resistant cells is detected by observing droplet shrinkage under microscopy. We validated this method for three clinically important antibiotics in Escherichia coli isolates obtained from bloodstream infections and showed that it can detect resistant subpopulations as infrequent as 10⁻⁶ using only 200 to 300 droplets. Additionally, we designed a multiplex microfluidic chip to increase the throughput of the assay.
Competing Interest Statement
The authors (SA, NFK, MT, and DIA) have a pending patent for this technology.
Funding Statement
This research was funded by grants from the Swedish Research Council (grant 2021-02091) and Knut and Alice Wallenberg Foundation (grant 2018.0168) to DIA and the European Research Council (ERC) under the European Unions Horizon Europe research and innovation programme (PHOENIX grant agreement No 101043985) to MT. We also acknowledge help from the BioImage Informatics Facility, a unit of the National Bioinformatics Infrastructure Sweden NBIS, with funding from SciLifeLab, National Microscopy Infrastructure NMI (VR-RFI 2019-00217), and Chan Zuckerberg Initiative DAF (DAF2021-225261, DOI 10.37921/644085ggkbos, an advised fund of Silicon Valley Community Foundation, DOI 10.13039/100014989). U-PRINT carried out 3D printing: Uppsala University's 3D printing facility in the scientific field of medicine and pharmacy. We acknowledge Myfab Uppsala for providing facilities and experimental support. Myfab is funded by the Swedish Research Council (2019-00207) as a national research infrastructure.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
